This trial is testing a new drug for Lupus called BIIB059. The objective is to see if it is more effective than a placebo in reducing disease activity. There are also secondary objectives to see if it has early onset of efficacy, if it works on specific parts of the body, and if it has other benefits. Finally, they will assess the safety and tolerability of the drug.
Research Site (+35 Sites)Medical DirectorBiogen